Vyvanse (Lisdexamfetamine): Clinical Overview
Vyvanse is FDA-approved for ADHD in patients ≥6 years and moderate-to-severe binge eating disorder (BED) in adults, with methylphenidate remaining first-line for ADHD in most international guidelines, while lisdexamfetamine serves as an alternative stimulant option. 1
Approved Indications
Vyvanse has two FDA-approved indications 1:
- ADHD: Adults and pediatric patients ≥6 years of age
- Binge Eating Disorder: Adults only with moderate-to-severe BED
Important limitation: Vyvanse is NOT indicated for weight loss. Use of sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events 1.
Dosing Recommendations
ADHD (Adults and Pediatric ≥6 years) 1
- Starting dose: 30 mg every morning
- Titration: Increase by 10-20 mg weekly
- Therapeutic range: 30-70 mg/day
- Maximum dose: 70 mg/day
Binge Eating Disorder (Adults) 1
- Starting dose: 30 mg every morning
- Titration: Increase by 20 mg weekly
- Therapeutic range: 50-70 mg/day
- Maximum dose: 70 mg/day
Renal Impairment Adjustments 1
- Severe renal impairment: Maximum 50 mg/day
- End-stage renal disease (ESRD): Maximum 30 mg/day
Available Formulations 1
- Capsules: 10,20,30,40,50,60,70 mg
- Chewable tablets: 10,20,30,40,50,60 mg
Mechanism and Pharmacokinetics
Lisdexamfetamine is a prodrug that is therapeutically inactive until enzymatically hydrolyzed primarily in the blood to active d-amphetamine 2, 3. This conversion is unaffected by gastrointestinal pH and normal transit times 2. The prodrug design provides:
- Duration of action: 12-14 hours (13 hours in children, 14 hours in adults) 2
- Once-daily dosing: Consistent plasma concentrations throughout the day 4
- Reduced abuse potential: Compared to immediate-release d-amphetamine due to slow, controlled release 3, 4
Contraindications
Absolute contraindications 1:
- Known hypersensitivity to amphetamine products or Vyvanse ingredients (anaphylaxis, Stevens-Johnson Syndrome, angioedema, urticaria reported)
- Current MAOI use or within 14 days of stopping MAOIs (risk of hypertensive crisis)
Warnings and Precautions
Boxed Warning: Abuse, Misuse, and Addiction 1
Vyvanse has high potential for abuse and misuse leading to substance use disorder. Before prescribing:
- Assess each patient's risk for abuse, misuse, and addiction
- Educate patients/families about risks and proper storage/disposal
- Throughout treatment, reassess risk and monitor for signs of abuse
Cardiovascular Risks 1
Avoid use in patients with 1:
- Known structural cardiac abnormalities
- Cardiomyopathy
- Serious cardiac arrhythmia
- Coronary artery disease
- Other serious cardiac disease
Sudden death has been reported in patients with structural cardiac abnormalities treated with CNS stimulants at recommended ADHD dosages 1.
Prior to treatment: Assess for presence of cardiac disease 1
During treatment: Monitor blood pressure and heart rate regularly. CNS stimulants cause mean increases of 2-4 mmHg in blood pressure and 3-6 bpm in heart rate, though some patients experience larger increases 1.
Psychiatric Adverse Reactions 1
Before initiating Vyvanse, screen for 1:
- Risk factors for developing manic episodes
- Comorbid or history of depressive symptoms
- Family history of suicide, bipolar disorder, or depression
New psychotic or manic symptoms: May occur in ~0.1% of patients without prior psychiatric history. If symptoms occur (hallucinations, delusional thinking, mania), consider discontinuing Vyvanse 1.
Pre-existing psychosis: CNS stimulants may exacerbate behavior disturbance and thought disorder 1.
Growth Suppression in Pediatric Patients 1
Closely monitor height and weight in pediatric patients. Pediatric patients not growing or gaining weight as expected may need treatment interruption 1. Critical caveat: Pediatric patients <6 years experienced more long-term weight loss than patients ≥6 years 1.
Peripheral Vasculopathy 1
Careful observation for digital changes is necessary. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for patients developing signs/symptoms of peripheral vasculopathy, including Raynaud's phenomenon 1.
Tics and Tourette's Syndrome 1
Before initiating: Assess family history and clinically evaluate for tics or Tourette's syndrome. Regularly monitor for emergence or worsening. Discontinue if clinically appropriate 1.
Serotonin Syndrome 1
Increased risk when co-administered with serotonergic agents (SSRIs, SNRIs, triptans) or during overdose. If it occurs, discontinue Vyvanse and initiate supportive treatment 1.
Common Adverse Effects
ADHD Population (≥5% incidence, ≥2x placebo) 1:
- Decreased appetite
- Insomnia
- Dry mouth
- Decreased weight
- Irritability
- Nausea
- Upper abdominal pain
- Anxiety
- Dizziness
- Diarrhea
- Vomiting
BED Population (≥5% incidence, ≥2x placebo) 1:
- Dry mouth
- Insomnia
- Decreased appetite
- Increased heart rate
- Constipation
- Feeling jittery
- Anxiety
Most adverse events are mild to moderate in intensity and transient 3.
Drug Interactions
pH-Altering Agents 1
Acidifying agents (decrease amphetamine blood levels):
- Gastrointestinal: Guanethidine, reserpine, glutamic acid HCl, ascorbic acid
- Urinary: Ammonium chloride, sodium acid phosphate, methenamine salts
Alkalinizing agents (increase amphetamine blood levels):
- Gastrointestinal: Sodium bicarbonate
- Urinary: Acetazolamide, some thiazides
Adjust Vyvanse dosage accordingly when co-administered with pH-altering agents 1.
Place in Therapy
ADHD Treatment Algorithm
International guidelines position 5, 6:
- First-line: Methylphenidate (MPH) remains first-line in most Asian guidelines (Malaysia, Singapore, India, Korea) 5
- Japan: Lisdexamfetamine (LDX) is approved with maximum dose 70 mg/day 5
- General approach: Stimulants (MPH or amphetamines) are first-line for ADHD when medication is indicated after behavioral/environmental interventions fail 6
Lisdexamfetamine-specific evidence 7, 8:
- In EU, lisdexamfetamine is indicated for children ≥6 years when response to previous MPH is clinically inadequate 7
- Demonstrated greater efficacy than atomoxetine (prospective comparison) and OROS-MPH (post hoc comparison) in treatment-inadequate responders 7
- In adults, response was similar in treatment-naïve patients and those who failed previous ADHD therapies including MPH 8
Alternative Treatments
- Other stimulants: Methylphenidate formulations (IR, ER, LA, OROS)
- Non-stimulants: Atomoxetine, guanfacine extended-release, clonidine extended-release
- Non-pharmacological: Parent training, academic interventions, social skills training, cognitive behavioral therapy, biofeedback
For BED 9:
- GLP-1 agonists
- Naltrexone
- Antidepressants
- Antiseizure medications
Note: Treatment guidelines for BED lack substantial recommendations beyond lisdexamfetamine 9.
Monitoring Requirements
Baseline Assessment 1
- Cardiac disease screening (history, physical exam)
- Psychiatric screening (psychosis, bipolar disorder, depression risk factors)
- Family history assessment (tics, Tourette's syndrome)
- Baseline blood pressure, heart rate, height, weight
Ongoing Monitoring 1
- Blood pressure and heart rate at each visit
- Height and weight in pediatric patients (closely monitor growth)
- Signs/symptoms of abuse, misuse, addiction
- Emergence of psychiatric symptoms
- Digital changes (peripheral vasculopathy)
- Tics or Tourette's symptoms
Special Populations
Pregnancy 1
May cause fetal harm.
Lactation 1
Breastfeeding not recommended.
Pediatric <6 years 1
Not indicated. Experienced more long-term weight loss than older children.